|
| 37539492 | Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir. | J Antimicrob Chemother | 2023 |
| 36259527 | Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. | Clin Infect Dis | 2023 |
| 37207617 | Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial. | Clin Infect Dis | 2023 |
| 37200995 | Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. | EClinicalMedicine | 2023 |
| 36852107 | Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study. | | 2023 |
| 34882940 | HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. | HIV Medicine | 2022 |
| 35529864 | Inversed Ratio of CD39/CD73 Expression on γδ T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease Progression. | Frontiers in Immunology | 2022 |
| 35544387 | Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. | New England Journal of Medicine | 2022 |
| 33896276 | Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study. | AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV | 2022 |
| 34656207 | Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. | Lancet HIV,The | 2021 |
| 32106695 | Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy. | AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV | 2021 |
| 34120186 | Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. | J Antimicrob Chemother | 2021 |
| 34146314 | [What to do in the case of treatment failure]. | MMW Fortschritte der Medizin | 2021 |
| 33987636 | Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials. | Clinical Infectious Diseases | 2021 |
| 34346028 | Correction to: Treatment modifcation after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017. | Infection | 2021 |
| 33236659 | High prevalence of recreational and illicit drug use in German people living with HIV with a potential for drug-drug interactions with antiretroviral therapy. | International Journal of STD and AIDS | 2021 |
| 33323070 | High prevalence of comorbidities and use of concomitant medication in treated people living with HIV in Germany - results of the BESIDE study. | International Journal of STD and AIDS | 2021 |
| 35234092 | Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes. | HIV Research and Clinical Practice | 2021 |
| 34557563 | Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study. | Open Forum Infectious Diseases | 2021 |
| 34496848 | Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance. | AIDS Research and Therapy | 2021 |
| 32613529 | Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017. | Infection | 2020 |
| 32017355 | The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. | HIV Medicine | 2020 |
| 32235038 | Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice. | Antiviral Therapy | 2020 |
| 31606734 | Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. | Clinical Infectious Diseases | 2020 |
| 32965277 | Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study. | Open Forum Infectious Diseases | 2020 |
| 32504574 | Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. | Lancet HIV | 2020 |
| 30932951 | Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. | AIDS | 2019 |
| 29912307 | Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age â¿¥50 Years: Final 96-Week Results of the NEAT022 Study. | Clin Infect Dis | 2019 |
| 30734998 | Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. | HIV Medicine | 2019 |
| 31068272 | Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. | Lancet HIV | 2019 |
| 31305329 | Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. | AIDS | 2019 |
| 29746267 | Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis. | | 2018 |
| 28851009 | Reply to Letter 'Morning dosing for dolutegravir-related insomnia and sleep disorders' by Capetti et al. | HIV Medicine | 2018 |
| 29925489 | Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas | Lancet HIV,The | 2018 |
| 30101539 | Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. | HIV Medicine | 2018 |
| 30319119 | Antiretroviral switch studies do matter. | Lancet HIV,The | 2018 |
| 28290130 | The "Choosing Wisely" initiative in infectious diseases. | Infection | 2017 |
| 28867499 | Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori | Lancet, The | 2017 |
| 28597280 | [Treatment of HIV-infected patients: metabolism, bone, cardiovascular - what is part of routine care?] | MMW Fortschritte der Medizin | 2017 |
| 28750935 | Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. | Lancet | 2017 |
| 28329090 | Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. | Clinical Infectious Diseases | 2017 |
| 29112070 | Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. | AIDS | 2017 |
| 27860104 | Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. | HIV Medicine | 2017 |
| 27650285 | HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. | Journal of Hepatology | 2017 |
| 28259776 | Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-i | Lancet HIV,The | 2017 |
| 27749561 | Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study. | Medicine (Baltimore) | 2016 |
| 27367993 | Analysis of contemporary HIV/AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines. | Medicine (United States) | 2016 |
| 26854810 | Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. | AIDS | 2016 |
| 26895510 | Which HIV patients should be screened for osteoporosis: an international perspective. | | 2016 |
| 26481253 | Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome. | Infection | 2016 |